Study: Health care experience disappoints 81% of consumers
CHICAGO — GE Healthcare Camden Group and Prophet on Wednesday published the results of a study that found about 81% of the people they surveyed are unsatisfied with their health care experience.
The study also found a gap between what providers thing they are offering and how consumers perceive the quality of their offerings, with providers overestimated consumers’ opinion on quality by more than 20%.
“There is a misperception among providers about how well they are truly meeting consumer expectations,” Prophet’s healthcare practice co-lead Jeff Gourdji said. “Although they acknowledge its importance, providers are finding it challenging to focus on patient experience in the face of so many competing priorities.”
In the past several years, the healthcare landscape has seen a growth in consolidation, as well as a dip in patient satisfaction, and experts who worked on the study attribute that to the patient’s growing desire to be more involved in their health care. Additionally, those involved with the study emphasized the imperative for providers to keep up with a rise in healthcare consumerism and patients’ increased focus on experience.
“The results of our study prove that to be successful, healthcare providers need to modernize their approach to patient experience,” GE Healthcare Camden Group president Laura Jacobs said. “Creating better and more holistic experiences doesn’t just mean happier patients. It translates to increased capacity, lower operating costs, improved financial performance, and higher employee satisfaction and retention. For healthcare providers, the key to profitability and longevity lies in their ability to deliver a superior consumer experience.”
Lupin completes Gavis acquisition
MUMBAI and BALTIMORE — Lupin announced Wednesday that it had completed its acquisition of Gavis, which includes Gavis Pharmaceuticals and Novel Laboratories, for about $880 million.
Lupin said the acquisition will grow the company’s footprint in the U.S. generics market and expands its dermatology, controlled substance product and high value and niche generics pipeline. With the acquisition, Lupin also gains its first manufacturing site in the United States — Gavis’ New Jersey manufacturing facility.
The new combined company will have over 120 products on the market and a pipeline with the fifth-largest number of abbreviated new drug application (ANDA) filings with the Food and Drug Administration.
“We are very pleased to have completed our acquisition of Gavis,” Lupin CEO Vinita Gupta said. “The Gavis portfolio augments our US business and niche generic pipeline. We plan to leverage the formulation expertise of Gavis to enhance both Lupin's generic as well as specialty pipeline.”
Psi Bands line extends nausea-relieving bands with new camouflage look
PACIFIC GROVE, Calif. – Psi Bands recently released a new band design named “Heart Land” – a camouflage-style band punctuated with hearts.
The FDA-cleared medical bands are worn on both wrists at the Nei-kuan acupressure point to help relieve nausea. A package of two generally retails for a suggested $15, the company stated.
Psi Bands are available nationwide at CVS, Target, Babies “R” Us, REI and Amazon, Psi Bands reported. The new Heart Land design just launched on Amazon.
Loading Post Please Wait...